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Peroxisome proliferator-activated receptor-gamma (PPARγ) exerts multiple functions in determination of cell fate, tissue
metabolism, and host immunity. Two synthetic PPARγ ligands (rosiglitazone and pioglitazone) were approved for the therapy
of type-2 diabetes mellitus and are expected to serve as novel cures for inﬂammatory diseases and cancer. However, PPARγ
and its ligands exhibit a janus-face behaviour as tumor modulators in various systems, resulting in either tumor suppression
or tumor promotion. This may be in part due to signaling crosstalk to the mitogen-activated protein kinase (MAPK) cascades.
The genomic activity of PPARγ is modulated, in addition to ligand binding, by phosphorylation of a serine residue by MAPKs,
such as extracellular signal-regulated protein kinases-1/2 (ERK-1/2), or by nucleocytoplasmic compartmentalization through the
ERKactivatorsMAPKkinases-1/2(MEK-1/2).PPARγ ligandsthemselvesactivatetheERKcascadethroughnongenomicandoften
PPARγ-independent signaling. In the current review, we discuss the molecular mechanisms and physiological implications of the
crosstalk of PPARγ with MEK-ERK signaling and its potential as a novel drug target for cancer therapy in patients.
Copyright © 2008 E. Burgermeister and R. Seger. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
1.1. Thejanus-faceofPPARγ:tumorsuppressorversus
tumorpromoteractions
The metabolic and cell fate regulatory functions of PPARγ
place this nuclear receptor (NR) [1, 2] at the cross-road of
life style and diabetic comorbidity risks, which are assumed
to result from the diet and/or chronic inﬂammation-induced
sequence of preneoplastic lesions towards manifested cancer
[3]. Since decades, the association of aberrant insulin signal-
ingindiabeticsandincreasedcancerriskhasbeenstated,and
recently validated in patient studies with respect to colon,
pancreas, breast, endometrium, prostate, liver, and bladder
(see,e.g.,[4–7]).AlthoughPPARγ playsanimportantpartin
the transmission of insulin responses and physiological diet,
little direct evidence exists relating these factors to PPARγ
activation and the risks of the development of cancer [6–8].
One of the reasons for the lack of knowledge on the role of
PPARγ is that a bona ﬁde high-aﬃnity natural ligand(s) for
PPARγ has not been identiﬁed yet [2].
PPARγ can be activated by low-aﬃnity ligands such as
unsaturated long-chain fatty acids derived from nutrient
uptake (e.g., linoleic acid) and/or inﬂammatory reactions
(e.g., 15-deoxy-Δ(12,14)-prostaglandin J2) [9, 10]. However,
those do not induce the full activity of PPARγ in most
systems examined [2]. As of today, modulation of PPARγ
activity is mediated by synthetics drugs, and among them
the thiazolidinediones (TZDs) rosi- and pioglitazone are
considered to be potent and selective PPARγ agonists [2].
These drugs were approved as insulin sensitizers for the
treatment of type-2 diabetes mellitus [11]a n dh a v eb e e n
proven helpful in vascular and atherogenic complications
[12, 13]. However, TZD drugs can also exert protumorigenic
actions in certain rodent models [14, 15]. In addition,
the safety of the TZDs has been recently evaluated in
clinical studies aimed to examine cancer prevalence in
diabetic patients under TZD use [16–18]. One study stated
a signiﬁcant association of cancer risk in women under
any TZD treatment (1003 patients) [17], while the other
two stated no signiﬁcant associations (126,971 patients [16];
87,678 patients [18]). On the other hand, patients with
long-term intake of nonsteroidal anti-inﬂammatory drugs
(NSAIDs), cyclooxygenase (COX) inhibitors that prevent
endogenous eicosanoid production and may act also as
low-aﬃnity PPARγ ligands, were reported to proﬁt from a
reduced risk for colon cancer formation [19].2 PPAR Research
These paradoxical eﬀects resulting from PPARγ acti-
vation are derived from a complex balance of anti-versus
protumor functions of PPARγ protein and its ligands in a
given system. The latter are also related to the interaction of
PPARγ with other oncomodulating proteins (such as MEK1
and βcatenin). In the current review, we will discuss this
janus-faced role of PPARγ and its ligands in cancer with a
major focus on its crosstalk with the ERK signaling cascade,
whichisacentralsignalingpathwayderegulatedinamajority
of tumor types in humans.
1.2. TheERKcascadeandcancer
The MAPK cascades are central signaling pathways that
mediate the response of essentially all cellular processes
stimulated by extracellular ligand, including proliferation,
survival, diﬀerentiation, apoptosis, stress response, and even
oncogenic transformation. Four main cascades have been
identiﬁed to date, of which the Ras-Raf-MEK1/MEK2-
ERK1/ERK2 cascade (ERK cascade) is the most prominent
one in human cancers [20, 21]. Its multilevel organisation of
kinases guarantees signal ampliﬁcation and coherence, and
its scaﬀold proteins [22] organize the pathway into a 3D
module that enables crosstalk and direct interactions with
other central signaling pathways such as the PPARγs.
Within the MAPK family, the ERK cascade constitutes
a major signaling pathway, regulating cell proliferation and
s u rvi v a l ,a sw e l la sc e l la d h e s i o na n dm o t i l i ty ,d i ﬀerentiation,
embryonal development, and neuronal regulation [21, 23].
Its deregulation, mainly due to constitutive upregulation by
receptor kinase “gain of function” mutations, contributes
to cancer initiation and progression [24–26]. The majority
of human carcinomas harbour increased expression or
activating point mutations for the upstream components
of the ERK cascade (e.g., epidermal growth factor receptor
(EGFR/Her1), Her2/Neu/ErbB2, K-Ras, B-Raf) that culmi-
nate in a higher ERK activity in a large majority of human
tumors. The ERK cascade currently represents the main
targeted cascade (next to the angiogenic vascular endothe-
lial growth factor/receptor (VEGF/R) system) by second-
generation low molecular weight (LMW) kinase inhibitors
(e.g., geﬁtinib, erlotinib) and monoclonal (humanized)
mAbs directed against members of the EGFR family (e.g.,
herceptin), which are in clinical use against cancer (as
reviewed in [25, 27, 28]). Therefore, inhibitors of the ERK
cascade are likely to be beneﬁcial in combating most types of
cancer.
2. MECHANISMS OF CROSSTALK BETWEEN PPARγ
AND THE ERK CASCADE
The mechanism of action and the regulation of PPARγ have
attractedconsiderableattentionovertheyears.Althoughthis
protein was initially shown to act as a transcription factor,
studies using synthetic ligands suggested that it may exert its
function via activation of signaling as well [1, 2]. According
to the current knowledge, PPARγ signaling is mediated by
several distinct mechanisms (Figure 1). The best known
one is exerted by PPARγ protein itself, which is activated
by ligand binding, heterodimerizes with the retinoic X
receptor (RXR) and requires NR coregulator recruitment,
events that lead to binding and transcriptional activation
of PPAR-responsive elements (PPREs) in the DNA [29]
(Figure 1(a)). Simultaneous activation of the ERK cascade
(e.g., by mitogens) therein contributes to inhibition of this
classical genomic action through serine phosphorylation of
PPARγ (Figure 1(a)). Another mechanism is that PPARγ
interacts with other transcription factors at the DNA level,
whichleadstoPPRE-independentgenomicactionsofPPARγ
protein and its ligands [9, 10]( Figure 1(c)). Activation
of the ERK cascade participates in this mechanism by
phosphorylation of the latter transcription factors that
interact with PPARγ (Figure 1(c)). A third possibility is that
nuclearexportandcytoplasmicretentionofPPARγbyMEK1
[30] results in “oﬀ-DNA”-interaction of PPARγ with distinct
protein partners (e.g., cytoskeleton, lipid droplets, kinases),
leading to alternative cytoplasmic signaling (Figure 1(b)).
Finally, PPARγ ligands can function via activation of intra-
cellular signalling (e.g., the ERK cascade) by a PPARγ-
independent mechanism, which is derived from exogenous
application of ligands that bind to plasma membrane-bound
receptors[31](Figure 1(d)).Thelattermodeofactioncanbe
“nongenomic,” that is, involving cytosolic signaling cascades,
or“genomic,”thatis,convergingontheDNAbyactivationof
alternative (non-PPAR) transcription factors (Figure 1(d)).
As apparent from the above description, interaction with
the ERK cascade plays an important role in the regulation
and signal transmission of PPARγ and its ligands. Overall,
three main mechanisms of signaling crosstalk between the
ERK cascade and PPARγ were described so far as follows: (1)
phosphorylation of PPARγ (and its cofactors) by ERKs and
other MAPKs (p38, JNK); (2) nongenomic activation of the
ERK cascade by PPARγ ligands; and (3) compartmentaliza-
tion of PPARγ by the ERK cascade component MEK1. Those
are described in details in this section.
2.1. ThefunctionsofthePPARγ proteinand
itsregulationbyERKphosphorylation
Genetic and pharmacologic studies in cells, rodent models,
and human patients corroborated that the PPARγ protein
serves as a master regulator of adipocyte and macrophage
function in normal and pathophysiological conditions
(inﬂammation, type-2 diabetes, obesity, atherosclerosis) [1].
Its expression in mesenchymal stem cells also associated
this receptor with bone, skin, and muscle diﬀerentiation
[2]. This 50-kDa protein consists of (from N- to C-
terminal) the following: a transactivation function-1 (AF1)
harbouring an MAPK-phosphorylation motif PXSP, a zinc-
ﬁnger-type DNA-binding domain (DBD), a hinge region,
the ligand-binding domain (LBD), and a ﬂexible AF2
helix. Ligand-binding triggers the formation of the “charge
clamp” between the AF2 and the core LBD, an event
that enables the release of NR corepressors (NCoRs), het-
erodimerization with RXR, DNA-binding, NR coactivator
(NCoA) recruitment, and transactivation of promoters [29]
(Figure 1(a)). The LBD/AF2 interface also constitutes an
important docking interface with unusual coregulators such
as kinases and cell-cycle regulators (reviewed in [32]).E. Burgermeister and R. Seger 3
(a) Classical genomic
PPARγ-ligand
Ras
Raf
MEK1/2
ERK1/2
PPARγ/RXR
S84/114
P
PM
PPRE
(a)
(c) Classical non-genomic
Caveolae
Lipid
droplets
Cytoskeleton
PM
Ras
Raf
MEK1/2
MEK PPARγ
PPARγ
crm1
(b)
(b) Non-classical genomic
NCoA
Non-PPRE
PM
Ras
Raf
MEK1/2
ERK1/2 P
PPARγ TF
P
(c)
(d) Non-classical non-genomic
ROS
PM
GPCR
Ras
Raf
MEK1/2
ERK1/2
Ca2+
TF
P
Non-PPRE
(d)
Figure 1: Mechanisms of PPARγ-ERK signaling crosstalk: (a) serine phosphorylation of PPARγ by the ERK cascade suppresses the classical
genomic action of RXR/PPARγ heterodimers on PPREs in the DNA; (b) ERK cascade phosphorylation of promitotic and proinﬂammatory
transcription factors (TF) and NR coactivators (NCoA) modulates their interaction with PPARγ “On-DNA”; (c) nuclear export of PPARγ
by MEK1 may result in “Oﬀ-DNA” interactions of PPARγ with alternative protein partners in the cytoplasm; (d) PPARγ-independent ERK
cascade activation by PPARγ ligands through plasma membrane GPCRs, transactivation of the EGFR (black bars), or calcium signaling.
PPARγ positively regulates the expression of a vast
spectrum of target genes involved in immunity and inﬂam-
mation,diﬀerentiation,proliferation,apoptosis,cellsurvival,
and metabolism [10]. However, PPARγ can also repress
transcription by negatively interacting with several proin-
ﬂammatory [9] and promitotic transcription factors [33]
such as ETS, STAT, AP1, and NFκB( Figure 1(c)). Thereby,
t h i sf a c t o rp r o m o t e st e r m i n a ld i ﬀerentiation of various
normal and transformed cells of epithelial and mesenchymal
origin. PPARγ(−/+) knockout mice exhibit enhanced sus-
ceptibility to chemically induced tumorigenesis [34, 35], and
this enhanced susceptibility is observed also upon breeding
with other strains deﬁcient in tumor suppressors (such as
APC) [36]. In patients, PPARγ p r o t e i ni se x p r e s s e d( i n
varying levels) in leukemias, lipo- and osteosarcomas and in
many carcinomas. Gene polymorphisms within the human
population result in several “loss-of-function” PPARγ vari-
ants that are associated with metabolic diseases (insulin
resistance, lipodystrophy) [37] and cancers (e.g., colon,
stomach) [4, 5, 38, 39]. These data initially corroborated
PPARγ as a protective transcription factor.
In line with the latter ﬁndings, ERK- (and other MAPK-)
mediated phosphorylation of PPARγ reduces its genomic
activity. A panel of extracellular/environmental promitotic,
stress and inﬂammatory stimuli (growth factors, hormones,
cytokines, lipid mediators/eicosanoids, UV-radiation, ani-
somycin, acetaldehyde, etc.) trigger the activation of the
MAPK-family members: ERK, JNK, and p38 (Figure 1(a)).
These MAPKs phosphorylate (in humans) Ser 84 in the
PPARγ1 and Ser 114 in PPARγ2 isoform, which correspond4 PPAR Research
to Ser 82/112 in mouse and are both located in the AF1
region of the molecules. This phosphorylation results in
suppressionofthePPARγ’sabilitytotransactivatetargetgene
promoters and thereby its physiological functions (reviewed
by [40, 41]). In addition, phosphorylated PPARγ is assumed
to be more prone to other posttranslational modiﬁcations
(sumoylation, ubiquitination) and subsequent degradation
by the proteasome, an event that promotes its further down-
r e g u l a t i o nu p o nM A P K - a c t i v a t i o n[ 42, 43]. But these eﬀects
are not fully characterized yet. In any event, the inhibition of
PPARγ activity by MAPK phosphorylation is in accordance
with the anti-inﬂammatory and prodiﬀerentiation action
of PPARγ and has been veriﬁed for normal (ﬁbroblasts,
adipocytes, macrophages, hepatic stellate cells) as well as
cancer cell lines, various stimulating agents (as reviewed in
[31, 44]) and also in vivo [45, 46]. An additional level of
crosstalk is constituted by the fact that PPARγ cofactors,
such as steroid receptor coactivator (SRC) family members
(e.g., AIB/SRC3 in breast cancer), are phosphorylated by
MAPKs and thereby are altered in their ability to coactivate
transcription [47]( Figure 1(c)).
TheeﬀectofPPARγ phosphorylationbyMAPKswasalso
supported by several in vivo studies. For example, a “knock
in” of an unphosphorylable allele S112A in mice preserved
their insulin sensitivity in absence of lipogenesis (weight
gain) in a setting of diet-induced obesity [45]. In addition,
a recent study revealed “downstream of tyrosine kinases-
1” (Dok1) as an adapter protein in the insulin-signaling
pathway that inhibits S112 phosphorylation of PPARγ2i n
vivo [46]. Dok1 knockout mice on high fat remain lean
and insulin-sensitive, and Dok1 knockout mouse embryonal
ﬁbroblasts(MEFs)showdefectiveadipogenicdiﬀerentiation,
increased ERK activation and phosphorylation of PPARγ2
on S112. Mutation of S112 of PPARγ2 blocked the lean
phenotype in Dok1 knockout mice, indicating that Dok1
promotes adipocyte growth and diﬀerentiation by coun-
teracting the inhibitory eﬀect of ERK on PPARγ. Another
current intriguing example is the identiﬁcation of parvinβ,
a focal adhesion protein (lost in breast cancer patients), that
increases the expression, S84 phosphorylation, and activity
of PPARγ1 through cyclin-dependent kinase 9 (CDK) and
suppressed breast cancer growth in vivo [48]. These data
indicate that MAPK-mediated S84/S114 phosphorylation
alters the activity of PPARγ1 / 2i nv i t r oa n di nv i v o .
In sum, these studies initially corroborated the role
of PPARγ as a tumor suppressor [2, 14], which may be
shut down by MAPK-phosphorylation [44]. However, more
recent evidence was collected, that PPARγ is a context-
speciﬁc tumor modulator, whose eﬀector proﬁle is com-
plemented and modiﬁed by PPARγ-independent eﬀects of
its ligands (e.g., TZDs and eicosanoids) and by reciprocal
regulation of PPARγ through members of the ERK cascade
as follows [31, 40].
2.2. PPARγ ligandsinﬂuencecellularprocessesvia
anongenomicactivationoftheERKcascade
A second mechanism of crosstalk between PPARγ and the
ERK cascade comprises the direct activation of ERKs by
PPARγ ligands. In the past, ample data was collected on
the eﬀects of chemically distinct classes of PPARγ ligands
on cells. Diﬀerent ligands induce either cell growth and
proliferation or growth arrest and apoptosis in various
human and mouse cancer cell lines and xenografts (as exten-
sively reviewed in [14, 31]), and also modulate angiogenesis
in vitro and in vivo [49]. These eﬀects are dose-, time-,
and cell type-dependent, and manifest either in a PPARγ
receptor-dependent (“genomic”) or non-PPARγ receptor-
mediated (“nongenomic”) manner or in a combination
of both. The mechanisms that underlie these context-
dependent responses are largely unknown. One concept is
based on the claim that nongenomic PPARγ ligand eﬀects
manifest at higher micromolar concentrations (>10μM)
well above the low EC50’s necessary for classical genomic
actionsonPPARγ/RXRheterodimersatcharacterizedPPREs
in target genes (e.g., 80nM for rosiglitazone) [50, 51].
This assumption translated into the idea that, low doses
of PPARγ ligands, for example, that correspond to the
pharmacological doses prescribed for diabetic patients, exert
overtly beneﬁcial eﬃcacy, while supra-pharmacological high
doses evoke adverse eﬀects. For example, troglitazone was
retracted from the market due to hepatotoxicity, which was
not a TZD-class eﬀect but due to a drug-speciﬁc (possibly
“nongenomic”) adverse action [2]. However, the literature
provides examples for both pro- and antitumor actions of
PPARγ ligands at similar dose ranges in similar cellular
systems. Thus, an underlying principle for the separation of
genomic from nongenomic PPARγ ligand eﬀects is currently
not available.
The PPARγ ligand eﬀects are likely to be mediated
either (i) through so far unknown plasma membrane-
bound receptors (Figure 1(d)) or (ii) through cytoplasmatic
localized PPARγ protein (Figure 1(b)). Novel G-protein
coupled receptors, such as GPR30 for estradiol [52], TGR5
for bile acids [53], and GPR40 for free fatty acids [54], were
identiﬁed to function as alternative signal transducers for
NR-ligands. GPR40, a candidate PPAR ligand receptor, is
highly expressed in the pancreas but also in monocytes and
in the lower GI tract (e.g., ileum, colon) [55, 56]. Oleate, a
naturalPPARligand,increasesproliferationofMCF7human
breast adenocarcinoma through binding and signaling via
endogenous GPR40 [57]. TZDs were postulated as bona ﬁde
ligands for ectopic GPR40 in CHO cells and to signal via
Gαi/q proteins, cAMP, calcium, and ERK activation [58].
However, in vivo proof is lacking. In addition to GPCRs, also
plasmamembrane-boundclassicalNRsinteractwithspeciﬁc
a d a p t e ro rs c a ﬀold proteins in the cytoplasm and trigger the
initiation of proproliferative and survival signaling [59]. For
example, the estrogen receptor docks to modulator of non-
genomic action of estrogen receptor (MNAR) that recruits
Src and leads to activation of the p85 subunit of PI3K [60]
and the ERK cascade [61]. If this situation is also relevant for
PPARγ molecules remains to be shown. Many TZD eﬀects
actually target cytoplasmic proteins such as at mitochondria,
the proteasome, or the translational machinery. Thus, it is
possible that cytoplasmic PPARγ molecules are also involved
in the transduction of “nongenomic” TZDs signals.E. Burgermeister and R. Seger 5
Downstream of the initial ligand triggering event,
nongenomic responses to PPARγ ligands include transient
alterations in mitochondrial functions and activation of
stress (production of reactive oxygen species (ROS)) as
well as kinase signaling pathways promoting proliferation
and survival such as PI3K-PKB/AKT, ERK, p38, and JNK
[50, 51]. Rapid signaling initiated by ligands can be medi-
ated by membrane proximal events such as cleavage of
transmembrane proteinases (ADAMs), activation of GPCRs,
EGFR transactivation, calcium inﬂux, and activation of
protein tyrosine kinases (Pyk2, Src). Further downstream
eﬀects include PPARγ-independent induction of “early
response genes” such as c-Fos and Egr-1. In this context,
it was shown that PPARγ ligands enhance proliferation,
survival and drug resistance in cancer cells, for example,
by induction of the prosurvival and promitotic hormone
gastrin [62]. We showed that TZDs enhance drug resis-
tance in human colon adenocarcinoma HT29 cells in a
PPRE-independent but EGFR-dependent manner, involving
Src/MAPK-signaling [63]. In colon carcinoma cells, TZDs
induce matrix metalloproteinase 2 (MMP2) and membrane
type 1-MMP (MT1-MMP) activation and concomitantly
increase tumor cell invasion through generation of ROS and
activation of the ERK cascade [64]. On the other hand,
ERK cascade activation by TZDs may also translate into
growth inhibition and/or apoptosis [65–69]. It is currently
unknown which mechanism governs the decision for pro-
versus antiproliferative responses upon TZD application.
In addition to TZD drugs, also the physiological
eicosanoid-type ligands for PPARγ exert tumor-modulating
eﬀects through their ability to trigger ERK cascade activation
[70]. Eicosanoids are generated by cytoplasmic phospho-
lipase A2 and cyclooxygenases (COX1/2). Some of these
arachidonic acid metabolites act as endogenous PPARγ
ligands ((e.g., 15-deoxy-Δ(12,14)-PGJ2) [71]), while others,
like the prostaglandins of the E and D series, activate
the ERK cascade through prostanoid GPCRs at the cell
membrane [72]. 15-deoxy-Δ(12,14)-PGJ2 directly inhibits
inhibitor-κB kinase (IKK) in an intracellular fashion and
exerts various eﬀects on inﬂammation, cell growth, and
apoptosis independent of a prostanoid GPCR [71]. For
example, in human breast MCF7 adenocarcinoma cells, 15-
deoxy-Δ(12,14)-PGJ2 upregulates VEGF synthesis through
induction of heme oxygenase-1, an enzyme that stimulates
proliferationandangiogenesis,andtriggersERKphosphory-
lation in an PPARγ-independent fashion [73]. In sum, these
data point out to the important role for protumor eﬀects
of PPARγ ligands of the TZD- and eicosanoid-class in the
activation of ERK cascade-related proliferation and survival
pathways, which stand in sharp contrast to the otherwise
reported tumor suppressive eﬀects of the latter in similar
cellular systems [65–67].
In vivo preclinical and clinical data of TZDs support
the concept of an overlapping proﬁle of PPARγ receptor-
dependent and independent ligand signaling. In contrast
to the lessons from PPARγ(+/−) knockout mice [34, 35]
and the antineoplastic action of PPARγ receptor acti-
vation in vitro [33], ample in vivo data asserted that
many potent and selective PPARγ ligands actually promote
tumorigenesis. Thus, PPARγ ligands induce tumor growth
in rodent xenograft models [14] and enhance in vivo
angiogenesis [49]. In addition, TZDs act as procancerogenic
agents in wild-type and APC-deﬁcient mouse models of
colon carcinogenesis [74–77]. Importantly, clinical stud-
ies in humans failed to show a clear beneﬁt of TZD
monotherapy in cancer patients [14, 78, 79]. PPARγ lig-
ands are procarcinogenic in human bladder, as evaluated
by the PROactive study [12], and in the rodent bladder
[80, 81]. As a reaction towards the safety-toxicological
data collected in preclinical studies and clinical trials
regarding TZD use, the US Food and Drug Administra-
tion (FDA) (http://www.fda.gov/cder/present/DIA2004/15)
issued a warning of tumor-related adverse eﬀects of novel
potent PPARγ ligands that are currently in clinical trials
as novel antidiabetics or obesity cures (reviewed in [82])
[83,84].TheFDAclassiﬁedallPPARγ ligandsasmultispecies
and multiorgan carcinogens requiring strict dose ﬁnding for
therapeutical use in humans. However, the full molecular
mechanism of this interplay between tumor promoting ver-
sus suppressing action of PPARγ ligands is so far unknown.
2.3. Towardssolvingthetumorinitiation/suppression
paradoxofPP ARγ:interactionofPPARγ with
theERKcascadeincancer
Unlike the impression that is left by many articles to date,
PPARγ protein does not always act as a tumor suppressor,
and the PPARγ ligands are not always procancerogenic
independently of the receptor. Notably, the PPARγ itself
seems to be important for exacerbating mammary gland
tumor formation in bitransgenic mice expressing a con-
stitutive active PPARγ form independently of application
of an exogenous ligand [85]. An interesting in vitro study
corroborated the functional cooperation of the PPARγ
receptor and the ERK cascade in the promotion of epithelial-
mesenchymal transition (EMT) in the mouse small intestine
and rat intestinal epithelial cells, which was dependent
on an intact DNA-binding activity of the PPARγ receptor
protein [86]. In this system, PPARγ induced ERK1/2 phos-
phorylation by activating PI3K, Cdc42, and p21-activated
kinase (PAK), which in turn phosphorylated S298 of MEK1
that supports its activity [23]. Ectopic expression of dom-
inant negative MEK1 blocked EMT induced by PPARγ,
while constitutively active MEK1 overexpression promoted
a mesenchymal morphology. However, as evident in the
latter intriguing example, the exact molecular mechanisms
and physiological relevance of the cooperative interactions
between posttranslational regulation of NRs by kinases and
rapid nongenomic kinase activation by NR-ligands are so far
unknown.
Ample data supports the notion that mutual physi-
cal/allosterical associations between kinases and NRs exist
thattranslateintoreciprocalregulationoftheiractivities[87,
88]. For example, 3-phosphoinositide-dependent protein
kinase-1(PDK1),thatistheupstreamactivatorofAKT/PKB,
binds to and activates PPARγ during adipogenic diﬀeren-
tiation [89]. Complexes of cyclins and CDKs are cofactors
for and phosphorylate PPARγ in adipocytes [90, 91]. PPARγ6 PPAR Research
also interacts with and is activated by ERK5 [92, 93]i no r d e r
to inhibit (in conjunction with WNT signaling factors) the
proliferationoflungcancer(NSCLC)cellsandinﬂammation
in endothelial cells upon ﬂow (shear stress), indicative of
a protective function of ERK5-PPARγ cooperation. These
unusual NR cofactors [32], that also include retinoblastoma
protein and transcriptional elongation factors, directly inter-
act with regulatory domains in NRs and considerably add
to the pleiotropic eﬀector proﬁle of a given NR. Several
interaction partners for PPARγ protein have been identiﬁed
including prominent oncogenic modulators suchas βcatenin
[94, 95] and MEK1 [30]. Therefore, it is likely that PPARγ
interacts with or cooperates with several signaling pathways
and particularly the ERK cascade in order to induce or
preventoncogenictransformationdependentonthecelltype
and environment.
2.3.1. SpatialregulationofPPARγ activity:
MEKsexportPPARγ tothecytoplasm
Next to Ser84/114 phosphorylation and the nongenomic
ERK activation by PPARγ ligands, the direct interaction of
PPARγ with the ERK cascade component MEK1 constitutes
a third mechanism of crosstalk between PPARγ and the
ERK cascade. Subcellular compartmentalization is a major
mechanism in regulating cellular signaling. Interestingly,
PPARγ itself can regulate the membrane translocation of
other proteins such as NFκB in gut intestinal epithelial cells
[96] and PKC in macrophages [97]. Several reports have
demonstrated a signal-mediated translocation of PPARγ
between the nucleus and the cytoplasm in vitro (as reviewed
in [98]). In addition, it was shown that PPARγ is expressed
predominantly in the nucleus of nonneoplastic tissues,
whereas it is present in both the nucleus and the cytoplasm
of tumorous tissues in squamous cell carcinoma (SCC) of
the lung, indicative of a correlation of malignancy with
diﬀerential PPARγ compartmentalization [99]. Moreover,
a dominant negative PPARγ splice variant was described
in lung SCC patients, an event that leads to the loss of
apoptosis sensitivity in response to oxidative stress and
cisplatin [99]. Diﬀerential compartmentalization of PPARγ
was also described in gastric cancer patients [100]. The
ratio of cytoplasmic/nuclear PPARγ expression decreased in
the progression of intestinal metaplasia to undiﬀerentiated
cancers [100]. In salivary duct carcinoma, an aggressive
tumor type, PPARγ is highly expressed (80%) and topo-
graphically located in the cytoplasm [101], indicative of
an inactivation of its genomic activities in the nucleus.
Cytoplasmic PPARγ was also detected in the cytoplasm
(58%) of inﬁltrating breast carcinoma samples and was
proposed as an independent prognostic factor for patients
with ductal carcinoma [102]. However, the function of
this subcellular distribution of PPARγ molecules are yet
unknown.
The mechanism that may induce the changes in local-
ization of PPARγ upon stimulation, or upon neoplastic
t r a n s f o r m a t i o nw a so n l yr e c e n t l ye l u c i d a t e db yu s[ 30].
We showed that PPARγ is exported from the nucleus to
the cytoplasm by MEK1/2. This is induced by a reversible
interaction of PPARγ with MEK1 through association of the
AF2 of the ﬁrst with the N-terminal docking domain of
MEK1. This export to the cytoplasm (Figure 1(b))l e a d st o
r e d u c t i o ni ni t sg e n o m i cf u n c t i o ni nt h en u c l e u s[ 30]. We
also elucidated the molecular mechanisms of the export and
the physiological implications, but the question remained
is whether cytoplasmatically located PPARγ is subjected to
degradation or shunted to alternative signaling compart-
ments such as lipid droplets, ER/Golgi, cytoskeleton, or the
plasma membrane. To this regard, we tend to speculate that
alternative locations of PPARγ in the cell may determine the
balance between tumor-suppressive and tumor-promoting
functions.
2.3.2. Tumor-suppressivefunctionsof
PPARγ relatedtoERKsandMEKsinteraction
Due to the coexpression of the ubiquitous proteins PPARγ
andMEK1/2indiﬀerentorgansofthebody,itwasinteresting
to identify their coregulation in various physiological and
pathological processes, as described below.
Differentiation
Due to the lethality of MEK1 knockout mice [103]a n d
absence of phenotypes in MEK2 knockout mice [104], the
major focus of interest was directed towards the role of
MEK1 overexpression in vivo. Constitutively active MEK1
(S218E/S222E)hasbeenconditionallyoverexpressed(among
other tissues) in the skin and bone of mice [105]. All trans-
genic mice exhibited increased cell numbers (hyperplasia)
and cell size and a defect in terminal diﬀerentiation. Interest-
ingly, both in skin and in bone of mice, PPARγ was shown
to be an important player promoting diﬀerentiation [2].
In addition, the constitutively active MEK1 overexpressing
mice show dwarﬁsm and reduced bone size due to defective
ossiﬁcation and impaired chondrocyte diﬀerentiation. In
other systems, it was shown that osteoclast-speciﬁc PPARγ
knockout mice are characterized by increased bone mass
due to impaired osteoclast diﬀerentiation [106], suggesting
antagonistic eﬀects of PPARγ and MEK1 on diﬀerent bone
cell types: with PPARγ promoting osteoclast diﬀerentiation,
and MEK1 inhibiting chondrocyte diﬀerentiation.
Skin-restricted MEK1 transgenic mice exhibit hyperpro-
liferation, hyperkeratosis and of age papillomas at sites of
wounding [105, 107]. Vice versa, epidermis-speciﬁc knock-
out of MEK1/2 in mice [108]r e s u l t e di nh y p o p r o l i f e r a t i o n ,
apoptosis, skin barrier defects, and death, indicative of
a positive role of MEK1 in skin proliferation and tissue
homeostasis. PPARγ knockout mice are characterized by an
increased sensitivity to experimentally-induced skin tumors
[35], emphasizing the tumor suppressor and diﬀerentiation
promoting activity of PPARγ in the skin. These “mirror-
images”phenotypesintheorganswhereMEK1/2andPPARγ
are normally coexpressed may give some indication for the
antagonistic regulation of the two proteins, MEK promot-
ing proliferation and dediﬀerentiation, PPARγ promoting
terminal diﬀerentiation. In line with this idea, it was shownE. Burgermeister and R. Seger 7
that the kinase activity of MEK1 was actually dispensable
for the hyperproliferative and integrin-inducing eﬀects of
the MEK1 in mouse skin [109]. Instead, a kinase-dead
mutant of MEK1 elicited the same phenotype, indicative of
an involvement of other MEK1-functions such as scaﬀolding
inhibition of diﬀerentiation-promoting cellular factors.
In adipogenic diﬀerentiation systems originating from
(mesenchymal) stem cells, synergistic cooperations between
the MEK-ERK cascade and PPARγ have been described. In
ﬁbroblasts, diﬀerentiating towards the adipogenic lineage,
a positive cooperation between PPARγ and MEK1 exists
that facilitates the adipogenic program by MEK1-dependent
induction of the C/EBPα gene [110]. In bone marrow-
derived mesenchymal stem cells isolated from normal and
streptozotocin (STZ)-induced diabetic FVB/N mice, high
glucose enhanced adipogenesis, lipid accumulation, and
PPARγ expression via PI3K/AKT and ERK cascade signaling,
events that were all inhibited by the MEK-inhibitor PD98059
[111]. In diﬀerentiated C2C12 myocytes, the free fatty acid
palmitate reduces the mRNA levels of PPARγ-coactivator-
1α (PGC1α) and activated MEK, while the MEK inhibitors
PD98059 and U0126 prevented such downregulation of
PGC1α, indicative of a MEK-mediated inhibition of an
important NR coactivator protein for PPARγ in muscle
cells [112]. These ﬁndings corroborated that the MEK-ERK
cascade and PPARγ signaling pathways can syn- or antag-
onistically cooperate to control the balance of proliferation
and diﬀerentiation in an organ/cell type-speciﬁc manner.
Cellcycle
The ERK cascade participates in the regulation of cell
cycle at (i) G0/G1 and G1/S transitions in response to
mitogenic stimulation (as reviewed in [24]) and (ii) in the
process of Golgi fragmentation [113–115] during mitosis.
This is mediated in part by the nuclear translocation of
ERK upon cellular stimulation that promotes expression
of “immediate early” genes such as members of the AP1
family that activate the promoters of the G1 cyclins D and
E. However, the subcellular compartmentalization of ERK
signalingbyscaﬀoldproteins(KSR,MP1/p14,Sef)(reviewed
in [22]) indicates a novel mode of spatial separation of
substratespeciﬁtiesandsignaltranslation.Forexample,MP1
via the adapter protein p14 tethers MEK1 to endosomes
[116] and focal adhesions [117]. Sef translocates MEK1
to the Golgi apparatus, prevents nuclear translocation of
ERKs, and, thereby, favours phosphorylation of cytoplasmic
ERK substrates instead of nuclear ones [118]. The latter
subcellular localization-determining systems may thus be as
well exploited by the PPARγ-MEK1 nuclear export shuttle to
regulate the cell cycle.
The PPARγ receptor has been involved in the inhi-
bition of the G0/G1-transition by up-regulation of genes
coding for the CDK-inhibitors p18(INK4C) [119]a n d
p21(WAF1/CIP1) [120, 121], and in the inhibition of G1/S
transition through upregulation of the p27(KIP1) gene
[122, 123]. Upregulation of other genes implicated in cell
cycle control such as PTEN or members of the BCL-gene
family contributes to the growth-arresting and/or apoptosis-
inducing action of PPARγ ligands [15] .T h ec e l lc y c l e
modulatory actions of PPARγ are usually not mediated
through classical PPRE binding at the DNA but rather
through PPRE-independent “oﬀ-DNA” crosstalk to other
transcription factors [15] and through nongenomic eﬀects
in the cytoplasm, such as inhibition of translation initiation
[124, 125] and modulation of the proteasomal machinery
[126–128]. The latter processes may be mediated by ligand-
activatedcytoplasmicPPARγ moleculesorcytoplasmicalter-
native signal-transducers for PPARγ ligands. We therefore
hypothesize that, by nuclear export and cytoplasmic reten-
tion of PPARγ-MEK1 complexes to other MEK1-scaﬀolding
locations (e.g., at the Golgi, endosomes, focal adhesions),
the genomic PPARγ functions may as well be redirected in
favour of cytoplasmic signaling events. In sum, the cell cycle
modulating eﬀects of PPARγ protein and its ligands may be
caused by its diﬀerential subcellular compartmentalization
by MEK1.
2.3.3. Tumor-promotingfunctionsofPPARγ,
relatedtocrosstalkwiththeERKcascade
Metastasis
In contrast to the initial assumption of PPARγ mainly acting
as a tumor suppressor whose activity and/or expression is
lost in cancers, PPARγ expression and activity can also be
a negative predictor of cancer aggressiveness; and positive
cooperation between PPARγ and components of the ERK
cascade in malignant phenotypes takes place. For example,
strong nuclear PPARγ expression was detected in thyroid
carcinomas compared to normal tissue, and patient samples
of thyroid carcinoma-associated lymph node metastasis also
showed a higher percentage of PPARγ-positive staining than
other case categories [129]. PPARγ expression was also
elevated in human prostate cancer compared to normal
prostate [130]. In patients with invasive breast carcinoma,
cytoplasmic MT1-MMP and MMP9 expression positively
correlated with PPARγ levels [131]. These data corrob-
orated a positive relationship between PPARγ expression
and malignancy state in certain tumor entities, a fact that
was shown to be therapeutically exploitable by the use
of PPARγ antagonists or siRNA. This was described in
primary esophageal tumor specimen and in esophageal
cancer cell lines [132], in human primary squamous cell
carcinoma (SCC) and lymph node metastases [133]a n d
in hepatocellular carcinoma (HCC) samples [134], where
PPARγ expression is elevated compared to matched nor-
mal tissue. In all three cell systems, PPARγ antagonists
(T0070907,GW9662) and RNAi-mediated knock-down of
PPARγ levels reduced the invasiveness and adherence of cells
to the extracellular matrix, triggered anoikis, or inhibited
proliferation by decreasing the phosphorylation status of
focal adhesion kinase (FAK), MEK, and ERK. Therefore, in
tumors where elevated PPARγ and activated ERK and MEK
levels contribute to the malignant phenotype, inhibition of
PPARγ may be beneﬁcial as a therapeutic strategy (see also
Section 3).8 PPAR Research
Angiogenesis
The overall vascular protective and antiatherogenic eﬀects
of PPARγ ligands provide essential add-ons for the clin-
ical application as insulin sensitizers (reviewed in [13]).
However, the proangiogenic eﬀects of PPARγ ligands via
modulationoftheVEGF/VEGF-receptorsystem(thatsignals
via the ERK cascade) have gained recognition (reviewed
by [49]), which may be beneﬁcial for therapy of vascular
diseases (e.g., infarction) [135, 136] but detrimental in
cancer tissue. For example, in rat myoﬁbroblasts, rosigli-
tazone and 15-deoxy-Δ(12,14)-PGJ2 induce expression of
VEGF and its receptors (Flt1 and KDR, that signal via
the ERK cascade), and augment tubule formation on a
matrigel, indicative of a promoting function of PPARγ and
ERKs in angiogenesis [137]. In osteoblast-like MC3T3E1
cells, pioglitazone and ciglitazone augmented FGF2-induced
VEGF release in a PPARγ-dependent manner and enhanced
the phosphorylation of JNK [138]. In human RT4 bladder
cancer cells, VEGF mRNA and protein are upregulated by
PPARγ via activation of the VEGF promoter. Interestingly,
the MEK inhibitor PD98059 reduced PPARγ ligand-induced
expression of VEGF [139], indicative of a positive coopera-
tion of PPARγ-ERK pathways in angiogenesis. These positive
eﬀects on angiogenesis were examined also in two clinical
studies with rosiglitazone [140] and pioglitazone [136], in
whichitwasdemonstratedthatchronicadditionoftheTZDs
increased endothelial cell precursor counts and migration
in diabetic patients, raising concern on the proangiogenic
potential of TZDs.
Taken together, the data which revealed an antagonistic
cooperation of PPARγ and ERK signaling in several cell or
tissue-speciﬁc diﬀerentiation systems (skin, bone, muscle,
fat) is now challenged by the ﬁndings of positive cooperation
of the same components in tumor progression (metastasis,
angiogenesis). Thus, the role of PPARγ as a MEK/ERK-
regulated tumor suppressor seems to be of importance in
normal tissue or in prevention of tumor initiation, while in
advanced stages of certain tumors a synergistic cooperation
between PPARγ and the ERK cascade may contribute to
the malignancy of the disease. Future studies have to clarify
whether PPARγ agonists, PPARγ antagonists, or PPARγ
modulators/partial agonists (SPPARMs) with a selective
eﬀector proﬁle [141] may be of interest for the therapy of
certain tumor entities.
3. CLINICAL USE OF PPARγ INTERACTION WITH
THE ERK CASCADE AS A DRUG TARGET
Reactivation (“diﬀerentiation”) therapy targeting functional
PPARγ protein in cancer cells/tissues by exogenous appli-
cation of TZD-class PPARγ ligands was lately expected to
represent a novel approach to ﬁght cancer [142]. However,
diﬀerentiation-inducing monotherapy with TZDs did not
show the expected clinical beneﬁt [11]. Instead, evidence
accumulated that alternative (“nongenomic”) PPARγ signal-
ing pathways, crosstalk with the ERK cascade and elevated
PPARγ expression levels in certain tumor types (where
PPARγ is postulated to act as a prosurvival factor, e.g., in
hepatocellular carcinoma, squamous cell carcinoma), are the
cause for the observed tumor promoting eﬀects of PPARγ
ligands, and may explain the absence of clear therapeutical
beneﬁt of TZDs in cancer patients [78, 79, 143]. Therefore
combinationtherapyofPPARγligandswithkinaseinhibitors
may represent a novel strategy to circumvent the crosstalk of
PPARγ and ERK cascade signaling and limit PPARγ protein
activation to its classical diﬀerentiation-inducing feature
(Figure 2). This dual approach is expected to avoid (a)
ERK cascade-mediated downregulation of PPARγ, (b) MEK-
driven nuclear export and cytoplasmic retention of PPARγ
and (c) nongenomic ampliﬁcation loops of PPARγ ligands
towards the ERK cascade, but to promote (d) the growth-
arresting and proapoptotic genomic functions of PPARγ
and its ligands, and (e) the negative crosstalk of PPARγ
with promitotic and proinﬂammatory transcription factors
in the nucleus. This concept may not be suitable for tumor
typeswithelevated“malignant”PPARγ expression/activities.
However,duetothelackofclinicallyapprovedPPARγ antag-
onists, no statement can be currently made on the potential
therapeutical beneﬁt of PPARγ and kinase coinhibition.
3.1. Invitrostudies
The combination of PPARγ ligands and inhibitors against
receptor tyrosine kinases of the EGFR-family or cytoplasmic
tyrosine kinases (e.g., Abl) revealed some promising results
in leukemia and carcinoma cells. Geﬁtinib, an inhibitor of
the EGFR/Her1 kinase, exhibits antitumor activity in only
a fraction of 10–20% of patients with nonsmall cell lung
cancer (NSCLC) [144]. The mechanisms underlying this
resistance to geﬁtinib are not known. However, application
of rosiglitazone reduced the growth of the NSCLC A549
cells and potentiated the antiproliferative eﬀects of geﬁtinib
and increased PPARγ and PTEN expression in these cells,
indicative of a potential beneﬁt of this drug combination
also in cancer patients. MCF7 breast cancer cells stably
transfected with ErbB2/Her2 displayed reduced diﬀerentia-
tion and enhanced resistance to TZD-driven inhibition of
anchorage-independent growth [145] .H e r c e p t i n ,am o n o -
clonal antibody against Her2 kinase, sensitized cells for the
diﬀerentiation-promoting and growth-inhibitory eﬀects of
troglitazone. This concept also held true for chronic myeloid
leukemia (CML) cell lines, where TZD18 (a dual PPARα/γ
ligand) enhanced CDK-inhibitor p27(KIP1) expression and
inhibited cyclin E, cyclin D2 and CDK2 [122]. TZD18 syn-
ergistically enhanced the antiproliferative and proapoptotic
eﬀect of imatinib, a clinically used kinase inhibitor of the
Bcr-Abl fusion protein. Collectively, this work demonstrated
that the targeting of receptor tyrosine kinase signaling with
LMW inhibitors or monoclonal antibodies can improve the
sensitivity of cancer cells to PPARγ ligand-mediated growth
inhibition.
3.2. Invivorodentandclinicalstudies
The clinical outcome of selective MEK inhibitors in patients
studieswasdisappointing(CI-1040,PD0325901,AZD-6244)
( r e v i e w e di n[ 146, 147]). On the other hand, a Raf inhibitor,E. Burgermeister and R. Seger 9
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Figure 2: Model of the combination therapy using PPARγ ligand and ERK cascade inhibitors. The simultaneous inhibition of EGF receptor-
initiated ERK cascade activation by speciﬁc kinase inhibitors (-ibs) or antibodies (-MABs) and supply of PPARγ ligands (in tumors that
h a v ean e e df o rr e s t o r e dP P A R γ activity) will avoid: (a) ERK-mediated downregulation of PPARγ through Ser84/114 phosphorylation, (b)
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to (d) restore the diﬀerentiation-inducing and proapoptotic functions of PPARγ and its ligands, and (e) promote the transrepressive activity
of PPARγ on other promitotic and proinﬂammatory transcription factors (e.g., AP1, ETS, STAT, NFκB). Legend:Y e l l o wc i r c l e s= PPARγ-
ligand; TF = transcription factors; ROS = reactive oxygen species; GPCR = G protein coupled receptor; RPTK = receptor protein tyrosine
kinase; crm1 = exportin1; NSAID = nonsteroidal anti-inﬂammatory drug; COX = cyclooxygenase; -Ibs = LMW tyrosine kinase inhibitors;
MABs = monoclonal tyrosine kinase antibodies.
sorafenib, was recently approved for clinical use; and novel
selective Raf inhibitors are under development [148]. So
far no clinical studies were performed using MEK or Raf
inhibitors in combination with PPARγ ligands. However,
successful treatment data in mouse models or patients are
available for combinations of PPARγ ligands and three
other types of inhibitory drugs: classical chemotherapeutics,
COX-inhibitors (NSAIDs), and established tyrosine kinase
inhibitors (imatinib, geﬁtinib, herceptin).
NSAID/COX-inhibitors have been shown to reduce
the risk for colon carcinoma formation, however at the
expense of gastric ulcer and cardiovascular complications
[19]. Several NSAIDs are also low-aﬃnity PPARγ ligands,
a fact that led to the speculation that a part of the
clinical proﬁle of these compounds is related to low-level
activation of PPARγ [19]. Therefore, clinical trials with
combination therapies were initiated to exploit PPARγ
activation and simultaneous blockage of the promitotic and
proinﬂammatory COX1/2-mediated eicosanoid production,
which contributes to nongenomic signaling in cancer tissues
(Figure 2). Pilot clinical studies with an angiostatic triple
combination of pioglitazone, rofecoxib (a selective COX2
inhibitor), and trofosfamide showed beneﬁt in patients with
angiosarcoma and hemangioendothelioma [151, 152]a n d
advanced sarcoma [153]. A phase-II trial with the same
triple combination in patients with metastatic melanoma
or soft-tissue sarcoma evinced disease stabilization [152],
indicative of a beneﬁcial eﬀect of COX2 inhibition (whose
eicosanoid metabolites activate the ERK cascade) and simul-
taneous PPARγ activation in sensitization of tumor cells
to diﬀerentiation and/or apoptosis. A recently published
outcome of a phase-II trial in high-grade glioma patients
(glioblastoma or anaplastic glioma) under pioglitazone and
rofecoxib combined with chemotherapy (capecitabine or
temozolomide) also stated some disease stabilization [157].
However, due to the severe side eﬀects of selective COX2-
inhibitors this therapeutic regimen may raise concerns.
Preclinical studies in rodents provided evidence for a
therapeutic potential of combination therapy with other
inhibitory agents. In mice xenografted with NSCLC A54910 PPAR Research
Table 1: Combination therapy with PPARγ ligands.
Cancer type PPARγ ligand Combination Inhibitor type Reference
In vitro
CML TZD18 Imatinib Abl, other RPTKs [122]
NSCLC A549 Rosiglitazone Geﬁtinib EGFR/Her1 [144]
Breast MCF7 Troglitazone Herceptin Mab-Her2/ErbB2 [145]
In vivo (human xenografts or chemically-induced tumors in rodents)
NSCLC A549 Pioglitazone PX-866
Geﬁtinib
PI3K-p110α
Her1/EGFR
[149]
Breast (by NMU) Rosiglitazone Tamoxifen SERM [150]
Thyroid ATC RS5444 Paclitaxel Chemotherapeutic [120]
Clinical studies
Melanoma
Sarcoma
Pioglitazone Rofecoxib
Trofosfamide
COX2
Chemotherapeutic
[151–153]
Advanced Solid
tumors
LY293111 Irinotecan
Gemcitabine
Chemotherapeutic
Chemotherapeutic
[154–156]
Glioblastoma
Anaplastic Glioma
Pioglitazone
Rofecoxib
Capecitabine
Temozolomide
COX2
Chemotherapeutic
Chemotherapeutic
[157]
cells, the PI3K inhibitor PX-866 potentiated the antitumor
activity of geﬁtinib [149]. The glucose intolerance related to
PX-866 in mice was reversed by insulin and pioglitazone.
PX-866 in combination with insulin sensitizers may thus
be useful in facilitating the response to EGFR inhibition.
The antitumoral action of rosiglitazone on experimen-
tally induced mammary tumors induced by N-nitroso-N-
methylurea (NMU) in Sprague-Dawley rats was potentiated
bytheselectiveestrogen-receptormodulator(SERM)tamox-
ifen with respect to the extent of tumor cell apoptosis and
necrosis [150]. The PPARγ ligand RS5444 in combination
with paclitaxel had additive antiproliferative eﬀect in vitro
and minimized tumor growth in nude mice xenografts
of anaplastic thyroid carcinoma (ATC) cells [120]. These
preclinical studies underline that the combination of PPARγ
ligands and established anticancer drugs may be of clinical
beneﬁt also in cancer patients.
Interestingly, two studies provided already ﬁrst-line
evidence for the potential of an in vivo reactivation of
PPARγ protein function by simultaneous inhibition of the
COX pathway-mediated activation of the ERK cascade:
LY293111, an oral PPARγ ligand, leukotriene B4 receptor
antagonist and 5-lipoxygenase inhibitor, was validated for its
antineoplastic eﬃcacy in combination with chemotherapy
(irinotecan, gemcitabine) in preclinical models [154]a n d
evoked disease stabilization in patients with advanced solid
tumors [155, 156]. The NSAID R-etodolac inhibits growth
of prostate cancer (CWRSA6, LuCaP35) xenografts in mice
by downregulation cyclin D1. However, the combination
of R-etodolac with herceptin elicited an additive antitumor
eﬀect, reduced ERK phosphorylation and stabilized PPARγ
protein levels [158]. These therapeutic regimens inhibited
the eicosanoid-mediated activation of the ERK cascade, and
in conjunction with PPARγ activation, may provide a basis
for diﬀerentiation-inducing therapy in combination with
classical chemotherapeutics or biologicals.
So far no clinical evidence was published on the com-
bined use of ERK cascade inhibition and PPARγ activation
(in tumors with low PPARγ expression/activity) or PPARγ
inhibition (in tumors with high PPARγ expression/activity).
In the future, the combination of PPARγ ligands with kinase
inhibition selectively targeted by MABs against the EGFR
tyrosine receptor kinase family or LMW selective inhibitors
of the downstream ERK cascade, such as Raf and MEK, may
constitute a possible new approach to treat cancer.
4. CONCLUSION AND PERSPECTIVES
In conclusion, PPARγ emerges as a tumor-type and tumor-
stage-speciﬁc modulator that is regulated by at least three
mechanisms through the ERK cascade. Downregulation is
carried out through (1) MAPK-mediated Ser84/114 phos-
phorylation, (2) ERK cascade activation through PPARγ
ligands, and (3) cooperation of PPARγ with tumor mod-
ulating proteins (such as MEK1). The overlay of these 3
mechanisms of crosstalk is likely to determine the physio-
logical outcome of PPARγ eﬀector functions. Consequently,
interference with these interactions by LMW inhibitors,
antibodies,orpeptidomimetic drugsagainstproteindocking
interfaces may constitute a novel approach to redirect
PPARγ eﬀector functions from a protumorigenic towards
an antitumorigenic proﬁle. Simultaneous inhibition of ERK
cascade-mediated signaling is expected to prevent adverse
promitotic and prosurvival pathways triggered by PPARγ
and its ligands. This therapeutic approach is assumed to be
reasonable in tumors where the tumor-suppressor activities
of PPARγ are lost/reduced/dysfunctional and should be
restored.However,itmaynotbeapplicablefortumorswhere
high PPARγ expression/activity levels positively correlate
with the state of malignancy. Since no PPARγ antagonist or
PPARγ modulator is in clinical use so far, future studies have
toevaluatewhether(dependingonthetumortypeandstage)E. Burgermeister and R. Seger 11
the combination of the latter drugs with kinase inhibitors
may be of therapeutical beneﬁt in tumor entities with high
PPARγ expression.
ABBREVIATIONS
AF: Activation function
DBD: DNA binding domain
COX: Cyclooxygenase
ERK: Extracellular signal-regulated kinase
LBD: Ligand binding domain
MAPK: Mitogen-activated protein kinase
MEK: MAPK/ERK kinase
NSAID: Nonsteroidal anti-inﬂammatory drug
NCoA: NR coactivator
NCoR: NR corepressor
NR: Nuclear receptor
PPAR: Peroxisome proliferator-activated receptor
PPRE: PPAR responsive element
RXR: Retinoid X receptor
ERK cascade: Ras-Raf-MEK1/2-ERK1/2 cascade.
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